Takeda Pharmaceutical Company Limited (TAK)

$13.07

-0.16

(-1.21%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Takeda Pharmaceutical Company Limited

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1043.08B → 1111.18B (in $), with an average increase of 6.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -48.03B → 105.72B (in $), with an average increase of 145.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 34.1% return, outperforming this stock by 56.3%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 39.5% return, outperforming this stock by 62.7%

Performance

  • $13.05
    $13.18
    $13.07
    downward going graph

    0.15%

    Downside

    Day's Volatility :0.95%

    Upside

    0.8%

    downward going graph
  • $13.05
    $16.77
    $13.07
    downward going graph

    0.15%

    Downside

    52 Weeks Volatility :22.18%

    Upside

    22.06%

    downward going graph

Returns

PeriodTakeda Pharmaceutical Company LimitedSector (Health Care)Index (Russel 2000)
3 Months
-10.48%
0.5%
0.0%
6 Months
-2.32%
11.7%
0.0%
1 Year
-22.25%
6.2%
2.2%
3 Years
-23.16%
13.5%
-23.0%

Highlights

Market Capitalization
41.9B
Book Value
$4297.22
Dividend Share
184.0
Dividend Yield
4.82%
Earnings Per Share (EPS)
0.36
PE Ratio
36.75
PEG Ratio
3.23
Wall Street Target Price
18.24
Profit Margin
4.28%
Operating Margin TTM
9.44%
Return On Assets TTM
2.61%
Return On Equity TTM
2.76%
Revenue TTM
4.2T
Revenue Per Share TTM
1335.47
Quarterly Revenue Growth YOY
1.3%
Gross Profit TTM
2.4T
EBITDA
1.2T
Diluted Eps TTM
0.36
Quarterly Earnings Growth YOY
-0.12
EPS Estimate Current Year
0.0
EPS Estimate Next Year
1.98
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 24 Wall street analysts offering stock ratings for Takeda Pharmaceutical Company Limited(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
12
11
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 39.56%

Current $13.07
Target $18.24

Company Financials

FY18Y/Y Change
Revenue
1.8T
↑ 2.22%
Net Income
186.9B
↑ 62.59%
Net Profit Margin
10.56%
↑ 3.92%
FY19Y/Y Change
Revenue
18.9B
↑ 18.45%
Net Income
983.2M
↓ 41.61%
Net Profit Margin
5.2%
↓ 5.36%
FY20Y/Y Change
Revenue
30.6B
↑ 56.93%
Net Income
411.5M
↓ 59.46%
Net Profit Margin
1.34%
↓ 3.86%
FY21Y/Y Change
Revenue
28.9B
↓ 2.84%
Net Income
3.4B
↑ 749.9%
Net Profit Margin
11.76%
↑ 10.42%
FY22Y/Y Change
Revenue
29.2B
↑ 11.61%
Net Income
1.9B
↓ 38.81%
Net Profit Margin
6.45%
↓ 5.31%
FY23Y/Y Change
Revenue
30.2B
↑ 12.85%
Net Income
2.4B
↑ 37.8%
Net Profit Margin
7.87%
↑ 1.42%
Q3 FY22Q/Q Change
Revenue
6.9B
↑ 3.07%
Net Income
427.5M
↓ 41.21%
Net Profit Margin
6.16%
↓ 4.64%
Q4 FY22Q/Q Change
Revenue
8.4B
↑ 9.4%
Net Income
908.6M
↑ 92.94%
Net Profit Margin
10.86%
↑ 4.7%
Q1 FY23Q/Q Change
Revenue
7.2B
↓ 12.8%
Net Income
233.7M
↓ 73.86%
Net Profit Margin
3.26%
↓ 7.6%
Q2 FY23Q/Q Change
Revenue
7.3B
↑ 10.72%
Net Income
619.4M
↑ 187.13%
Net Profit Margin
8.44%
↑ 5.18%
Q3 FY23Q/Q Change
Revenue
1.0T
↓ 1.47%
Net Income
-48.0B
↓ 153.73%
Net Profit Margin
-4.6%
↓ 13.04%
Q4 FY23Q/Q Change
Revenue
1.1T
↑ 6.53%
Net Income
105.7B
↓ 320.11%
Net Profit Margin
9.51%
↑ 14.11%
FY18Y/Y Change
Total Assets
4.1T
↓ 5.72%
Total Liabilities
2.1T
↓ 13.2%
FY19Y/Y Change
Total Assets
125.0B
↑ 237.82%
Total Liabilities
78.5B
↑ 316.87%
FY20Y/Y Change
Total Assets
119.3B
↓ 7.58%
Total Liabilities
75.3B
↓ 7.06%
FY21Y/Y Change
Total Assets
116.6B
↑ 0.71%
Total Liabilities
69.8B
↓ 4.43%
FY22Y/Y Change
Total Assets
108.0B
↑ 2.06%
Total Liabilities
61.4B
↓ 3.11%
FY23Y/Y Change
Total Assets
104.8B
↑ 5.92%
Total Liabilities
57.1B
↑ 1.45%
Q3 FY22Q/Q Change
Total Assets
101.0B
↑ 3.72%
Total Liabilities
54.5B
↑ 1.64%
Q4 FY22Q/Q Change
Total Assets
103.0B
↓ 7.43%
Total Liabilities
55.9B
↓ 6.95%
Q1 FY23Q/Q Change
Total Assets
104.8B
↑ 3.35%
Total Liabilities
57.1B
↑ 3.75%
Q2 FY23Q/Q Change
Total Assets
102.5B
↑ 5.98%
Total Liabilities
54.5B
↑ 3.52%
Q3 FY23Q/Q Change
Total Assets
14.9T
↑ 0.54%
Total Liabilities
7.8T
↓ 0.89%
Q4 FY23Q/Q Change
Total Assets
14.2T
↓ 4.36%
Total Liabilities
7.5T
↓ 4.11%
FY18Y/Y Change
Operating Cash Flow
377.9B
↑ 44.57%
Investing Cash Flow
-93.3B
↓ 85.76%
Financing Cash Flow
-326.2B
↓ 212.53%
FY19Y/Y Change
Operating Cash Flow
3.0B
↓ 13.07%
Investing Cash Flow
-25.5B
↑ 2937.97%
Financing Cash Flow
26.5B
↓ 1003.13%
FY20Y/Y Change
Operating Cash Flow
6.2B
↑ 103.89%
Investing Cash Flow
2.7B
↓ 110.3%
Financing Cash Flow
-9.4B
↓ 134.12%
FY21Y/Y Change
Operating Cash Flow
9.1B
↑ 50.94%
Investing Cash Flow
3.6B
↑ 34.72%
Financing Cash Flow
-9.8B
↑ 8.27%
FY22Y/Y Change
Operating Cash Flow
9.2B
↑ 11.1%
Investing Cash Flow
-1.6B
↓ 150.35%
Financing Cash Flow
-8.8B
↓ 1.66%
FY23Y/Y Change
Operating Cash Flow
7.3B
↓ 13.0%
Investing Cash Flow
-4.6B
↑ 206.42%
Financing Cash Flow
-5.3B
↓ 33.74%
Q3 FY22Q/Q Change
Operating Cash Flow
1.5B
↑ 162.33%
Investing Cash Flow
-188.4M
↓ 71.28%
Financing Cash Flow
-359.2M
↓ 75.95%
Q4 FY22Q/Q Change
Operating Cash Flow
2.9B
↑ 71.15%
Investing Cash Flow
-1.3B
↑ 519.75%
Financing Cash Flow
-3.3B
↑ 738.45%
Q1 FY23Q/Q Change
Operating Cash Flow
2.2B
↓ 22.35%
Investing Cash Flow
-4.6B
↑ 260.06%
Financing Cash Flow
-49.5M
↓ 98.48%
Q2 FY23Q/Q Change
Operating Cash Flow
640.2M
↓ 68.54%
Investing Cash Flow
-1.8B
↓ 56.1%
Financing Cash Flow
-400.3M
↑ 775.42%
Q3 FY23Q/Q Change
Operating Cash Flow
198.9B
↑ 115.27%
Investing Cash Flow
-327.1B
↑ 22.73%
Financing Cash Flow
-140.7B
↑ 143.44%

Technicals Summary

Sell

Neutral

Buy

Takeda Pharmaceutical Company Limited is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
-9.17%
-2.32%
-22.25%
-23.16%
-28.97%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.41%
27.65%
34.11%
39.49%
77.94%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
5.13%
-5.51%
13.36%
13.36%
Zoetis Inc.
Zoetis Inc.
-7.43%
-2.98%
-11.32%
-9.68%
48.39%
Viatris Inc.
Viatris Inc.
-1.12%
27.59%
26.04%
-15.35%
-29.8%
Catalent, Inc.
Catalent, Inc.
-0.82%
42.09%
27.6%
-51.77%
23.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
36.75
36.75
3.23
0.0
0.03
0.03
0.05
4297.22
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.82
29.82
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
231.0
231.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
Buy
$41.9B
-28.97%
36.75
4.28%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.94%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.1B
13.36%
29.82
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.39%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.7B
-29.8%
231.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.97%
211.02
-31.77%

Institutional Holdings

  • Capital Research Global Investors

    0.46%

  • Goldman Sachs Group Inc

    0.27%

  • Mondrian Investment Partners Ltd

    0.26%

  • Millennium Management LLC

    0.21%

  • Morgan Stanley - Brokerage Accounts

    0.15%

  • Renaissance Technologies Corp

    0.11%

Corporate Announcements

  • Takeda Pharmaceutical Company Limited Dividends March,2022

    In the quarter ending March,2022. Takeda Pharmaceutical Company Limited has declared dividend of $0.33

    Read More

Company Information

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.

Organization
Takeda Pharmaceutical Company Limited
Employees
49095
CEO
Mr. Christophe Weber
Industry
Health Technology

Discover More

FAQs